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Abstract For successful transplantation, allografts
should be free of microorganisms that may cause harm
to the allograft recipient. Before or during recovery
and subsequent processing, tissues can become con-
taminated. Effective tissue recovery methods, such as
minimizing recovery times (\24 h after death) and the
number of experienced personnel performing recov-
ery, are examples of factors that can affect the rate of
tissue contamination at recovery. Additional factors,
such as minimizing the time after asystole to recovery
and the total time it takes to perform recovery, the type
of recovery site, the efficacy of the skin prep
performed immediately prior to recovery of tissue,
and certain technical recovery procedures may also
result in control of the rate of contamination. Due to
the heterogeneity of reported recovery practices and
experiences, it cannot be concluded if the use of other
barriers and/or hygienic precautions to avoid contam-
ination have had an effect on bioburden detected after
tissue recovery. Qualified studies are lacking which
indicates a need exists for evidence-based data to
support methods that reduce or control bioburden.
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Introduction
There are 13 Canadian tissue banks registered with
Health Canada that recover human tissue from donors
for use in transplantation, and 8 of them are accredited
by the American Association of Tissue Banks (AATB).
Commonly recovered tissues include skin, cardiac (the
heart), bone, and fibrous connective tissue. The purpose
of Health Canada’s regulatory initiative involving
human tissues is to minimize the potential health risks
to Canadian recipients of tissue allografts. The regula-
tions establish safety requirements such as tissue
retrieval (recovery) practices, among other critical
steps, to improve the ‘‘protection of the health and
safety of Canadian transplant recipients’’ (Government
of Canada 2013). The complete microorganism profile
of an allograft is termed the tissue’s bioburden. While
bioburden represents the type and quantity of microor-
ganisms associated with an allograft sample, contami-
nation denotes the simple presence of microorganisms
on or in the sample. Reduction due to antimicrobial
intervention (i.e., disinfection) can be assessed qualita-
tively in relation to improvement in contamination rate,
or quantitatively by determining the bioburden load
before and after an intervention. Tissues removed under
aseptic conditions may still be determined to be
contaminated following recovery and/or processing,
which contributes to allografts determined to be unsuit-
able (Mroz et al. 2008). Tomaximize safety and prevent
the loss of tissue allografts, tissue banking professionals
have implemented procedures and disinfectionmethods
to control, reduce or eliminate bioburden and, where
possible, have established minimum sterility assurance
levels for sterilization methods with a focus to reduce
the likelihood of provision of a contaminated allograft
for transplantation.
There are a variety of approaches available to test
tissue and determine allograft bioburden. The ‘‘Guid-
ance Document for Cell, Tissue and Organ Establish-
ments—Safety of Human Cells, Tissues and Organs for
Transplantation’’ published by Health Canada (2013)
describes responsibilities for registration, donor screen-
ing and testing, processing, packaging, labeling, quar-
antine, storage, reporting, records, and quality assurance
systems. In the Canadian regulations, tissue recovery is
included within the broad scope of ‘‘processing.’’
Initially, donor eligibility is assessed and includes
screening for infectious disease risks based on medical
and social (behavioral) history, physical examination,
the results of any diagnostic procedures performed, and,
if applicable, an autopsy (Government ofCanada 2013).
The guidelines recommend an interview and question-
naire that includes screening for risks associated with
contraindications/exclusion criteria. In addition, donors
must be tested for communicable diseases/infections
including human immunodeficiency virus-1 and -2,
hepatitis B and C viruses, and other communicable
diseases, using commercial tests that are appropriate and
effective. Upon recovery of certain tissue types from a
donor, it’s customary to assess microbiological con-
tamination by obtaining a swab culture of each tissue,
and the swab is later inoculated to a culture medium to
promote growth and determine bioburden. Microbio-
logical culture results can guide interventions to min-
imize the riskof a bacteriological pathogen transmission
to a recipient. Additional tests may be performed to
evaluate or provide information prior to processing or
storage in a tissue bank. Relative to Canadian tissue
banks, recovered tissues (such as a heart, bone, fibrous
connective tissue or skin) can be fashioned intomultiple
allografts for transplantation (e.g. the dissection of a
heart into one to four cardiac allografts for transplan-
tation into asmany recipients; bone can be cut and sized
for use in more than a dozen recipients).
Although allografts have been extensively used for
transplantation worldwide, best practices for tissue
recovery to control or prevent contamination and cross-
contamination have not been thoroughly examined and
published. One study showed a trend that an increased
number of people in the operating roomduring recovery
increasedmusculoskeletal allograft contamination, sug-
gesting that recovery variables may impact contamina-
tion rates and bioburden (Segur et al. 2000). In the
Canadian guidelines, control of contamination is
expected, but specific methods are not described.
In this review, we examined the methods used to
recover tissue from donors in an effort to determine the
most appropriate procedures that could minimize
allograft contamination/bioburden and optimize trans-
plantation potential.
Methods
Information sources and search
The search strategy was developed and reviewed by
SF and the tissue recovery working group at Canadian
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Blood Services. The search was applied to the
electronic databases MEDLINE and EMBASE from
1974 to July 25, 2014 including the following search
terms: ‘‘tissue recovery,’’ ‘‘bioburden reduction,’’
‘‘bioburden control,’’ ‘‘aseptic technique,’’ ‘‘clean-
ing,’’ ‘‘tissue banking,’’ ‘‘storage,’’ and ‘‘asystole’’,
among others. An additional reviewer (AG) performed
an updated search using the original search strategy to
include publications up to March 6, 2015. The full
search strategy is shown in Appendix A.
Study selection
Eight reviewers (KL, SM, SB, GR, BH, SF, CH and
JZ) independently screened each of the citations in
duplicate to identify studies that met all of the
following four inclusion criteria: (1) evaluated bone,
fibrous connective tissue, cardiovascular tissue or
skin; (2) included a tissue recovery parameter such as
ischemic time, body cooling, donor condition, skin
preparation, recovery site, instruments, and/or attire of
recovery personnel; (3) included a storage or transport
parameter such as storage medium or temperature,
packaging, shipping container or procedure, refriger-
ant to tissue ratio, duration of storage and/or trans-
portation; and (4) included outcomes in either patient
infection attributed to tissues, proportion of allograft
that did not meet release criteria due to bioburden load,
or microbe detection on tissues (bioburden rates, log
reduction, counts, antibiotic potency, initial contam-
ination rate versus final). A study was excluded if it
was an editorial, letter, conference abstract, or review.
During duplicate screening, if there was disagreement,
the full report was retrieved and an independent
assessment was repeated until consensus was reached.
Data abstraction
Design of data abstraction forms and evidence
tables were guided by the questions in the analytic
framework (Appendix B). Three reviewers (RB, DA
and AD) independently collected study characteristics
including the donor type, recovery site, tissues
collected, cold ischemic time, and warm ischemic
time. The bioburden analysis was summarized for
each study and data included sample preparation and
method, incubation period and temperature, species
identified, bioburden, and proportion of samples not
suitable for transplantation. Any discrepancies in data
abstraction were resolved by consensus.
Quality assessment
Following the screening process, clinical studies that
met the eligibility criteria were evaluated for quality
using the Grades of Recommendation, Assessment,
Development, and Evaluation (GRADE) assessment.
The GRADE quality of a study is dependent on the
consistency of the results, directness of the evidence,
and precision to inform recommendations (Guyatt
et al. 2011). There is no validated quality assessment
tool for laboratory-based studies because basic science
research is inherently considered level IV, or low
quality evidence (Balshem et al. 2011).
Table 1 Characteristics of laboratory studies
First author, year Country Sites Donor Location of recovery Tissue(s) recovered
Gaucher et al. (2012) France 1 Multi-organ NR Skin





Italy 1 Multi-organ NR Skin
Bravo et al. (2000) USA 1 Cadaveric NR Skin
Wester et al. (1998) USA 1 Cadaveric NR Skin
Armiger (1995) New Zealand 1 Cadaveric NR Cardiac (pulmonary
and aortic valves)
Niwaya et al. (1995) Japan 1 Organ NR Cardiac (pulmonary valves)
NR Data not reported
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Data analysis
Data abstracted from studies that qualified were
organized into tables presenting study characteristics,
bioburden analysis, recovery, storage and transport,
and finally, outcomes. Descriptive statistics include
the frequency and percentage of bioburden outcomes,
as well as mean proportions. A meta-analysis was not




A total of 6245 citations were reviewed after dupli-
cates were removed (Fig. 1). Twenty-eight citations
were selected for full text review, of which 19 were
included. These include seven laboratory studies and
12 clinical studies all of which are elaborated below.






















Fig. 1 Summary of search strategy
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did not fulfill the screening criteria and are described
in Appendix C. Following the updated search to
include articles up to March 6, 2015, an additional 429
articles were retrieved; however, none were identified
for full text evaluation.
Characteristics and culture methods of the studies
The studies selected were published between 1992 and
2013. Almost half of them (9/19) were from Europe,
with the remaining from Australia (4/19), Asia (3/19)
and North America (3/19). Of the 19 studies, seven
were laboratory studies and 12 were clinical studies
(Tables 1 and 2).
This review assessed the recovery methods for
multiple tissue types, which included heart (746
laboratory samples and 3857 samples for transplanta-
tion), bone (zero laboratory samples and 303,551
samples for transplantation), skin (448 laboratory
samples and zero samples for transplantation) and,
finally, fibrous connective tissue (zero laboratory
samples and 3315 samples for transplantation). Skin
allografts were included in four of the 19 studies,
whereas eight addressed cardiac tissues, and seven
studies analyzed musculoskeletal tissues.
The site where tissue recovery took place varied.
Recovery was performed in operating theatres for
living and organ donors, and in a morgue or an
operating room for cadaveric donors.
In all 19 studies, the presence of microorganisms
(including bacteria, and fungi) was determined by
placing pieces of tissue directly in culture media, or by
swabbing the tissue and placing the swab in culture
media. In one laboratory study, tissue fragments were
cultured to determine bioburden following recovery
(Jashari et al. 2007). Culturing details were not
reported in the remaining six laboratory studies. In
the 12 clinical studies, two studies cultured tissue
samples directly, one study cultured tissue swabs,
three studies cultured tissue samples and swabs, two
studies cultured tissues and tissue rinses or solutions,
and four studies did not report the sampling method for
culturing.
There was a variety of growth media used to culture
microorganisms (Appendix D). One laboratory study
reported thioglycollate media to culture bacteria, and
Sabouraud, trypto-casein and soy media for culturing
of fungi and yeast (Jashari et al. 2007). For clinical
studies, media types included thioglycollate agar,
Sabouraud agar, blood agar, chocolate agar, brewer’s
liquid culture media, reinforced clostridial media,
Stuart’s transport media, dextrose broth, Schaedler’s
broth, Kimmig plates or endo agar. Incubation of
cultures at temperatures between 20 and 37 C for one
to 21 days was reported in nine studies. Six laboratory
studies and four clinical studies did not report
incubation parameters.
Study outcomes
Contamination rates, bioburden and pre-recovery
conditions
Contamination rate following tissue recovery was
reported in only one laboratory study (Appendix E1).
This study found contamination rates in the transport
media following heart tissue recovery was an average
of 26.7 % (Jashari et al. 2007). The rates of contam-
ination following recovery were reported in 12 clinical
studies (Appendix E2). Cardiac tissue contamination
rates were on average, 19.9 % (range 13.9–42.9 %). In
addition, 54 % of heart valves recovered in a morgue
from multi-organ donors were reported as contami-
nated, while those in an operating room were
contaminated at a rate of only 12 % (Gall et al.
1995). Samples of recovered bone allografts were
contaminated an average of 19.4 % (Std. dev: 15 %;
range 4.7–49 %). One study examining fibrous con-
nective tissues (tendons) observed a contamination
rate of 2.7 % (Schubert et al. 2012).
The most commonly reported genera of microor-
ganisms identified in 10 clinical studies and one
laboratory study were (in order of prevalence):
Staphylococci, Streptococci, Pseudomonas, Bacillus,
Candida, Acinetobacter, Escherichia, Propionibac-
terium, Enterococci and Corynebacterium. Across
studies there was no apparent relationship between
species of microorganisms and pre-recovery condi-
tions. However, one study observed a higher rate of
pathogenic microorganisms (e.g. Staphylococcus aur-
eus, Escherichia coli, Candida, etc.) associated with
allografts recovered in the morgue compared to
recovery that took place in an operating room (33
and 20 %, respectively), and conversely a higher rate
of non-pathogenic microorganisms (e.g. Propionibac-
terium, Corynebacterium, etc.) in allografts recovered
in the operating room compared to recovery in the
morgue (31 and 7 %, respectively) (Bettin et al. 1998).
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Contamination rates may be correlated with the site
of tissue recovery. One study observed lower contam-
ination rates in heart valves recovered from multi-
organ donors in operating rooms (12 %) compared to
valves recovered from cadavers in an open mortuary
(54 %) (Gall et al. 1995). Another study found that
cardiac tissue recovered in the operating room from
multi-organ donors had contamination rates of
21.7 %, while tissue recovered from non-heart beating
(cadaveric) donors in the morgue had a higher
contamination rate of 33.3 % (Jashari et al. 2007). In
addition, studies with the lowest proportions of
contaminated tissues following recovery (2.7, 4.7
and 5 %) were performed in operating rooms (Gocke
2005; Schubert et al. 2012). Conversely, Bettin et al.
1998 reported that tissues recovered in operating
rooms were more contaminated (51 %) than tissues
recovered in morgues (40 %). However, as described
above, the study also showed that microorganisms
contaminating allografts from the morgue were more
likely to be pathogenic compared to the operating
room. Other confounding factors (e.g., trauma) that
could affect contamination rates were not analyzed.
Details regarding warm ischemic time (time period
from asystole to subjecting the tissue to cold rinse or
transport) were reported for five laboratory studies and
seven clinical studies. In clinical studies, the warm
ischemic time was consistently less than 24 h. Recov-
ery of skin tissue was performed within 24 h following
death in laboratory studies, and the warm ischemic
time was less than 15 h. Warm ischemic time periods
for bone tissue were less than 24 h. Similarly,
connective tissue was recovered within 24 h of death
in clinical studies (Schubert et al. 2012).
Cold ischemic time (the time interval from sub-
jecting cardiac tissue to cold rinse or transport solution
at recovery to the beginning of disinfection) was more
varied than that of the reported warm ischemic times.
The cold ischemic time period for skin tissue ranged
0.5–24 h, and was less than 24 h for cardiac tissues in
laboratory studies (Bravo et al. 2000; Castagnoli et al.
2003; Gaucher et al. 2012; Jashari et al. 2007).
Other procedures utilized to minimize tissue con-
tamination did not appear to correlate with contami-
nation rates, however, the details provided for each
study varied. For example, one laboratory study
indicated that recovery was performed with sterilized
equipment, although other precautions against con-
tamination were not reported, and resulted in an
average contamination rate of 26.7 % (Jashari et al.
2007). Others such as Bettin et al. (1998) reported a
number of precautions including the use of two sets of
instruments, double-gloves, skin decontamination and
sterile drapes. Despite these precautions, researchers
still observed relatively high allograft contamination
rates of 40 and 51 % of samples (cadaveric and organ
donors, respectively) (Bettin et al. 1998). Other
methods to reduce contamination included ensuring
that the sternotomy did not enter the trachea or
abdominal cavity during cardiac tissue recovery, or the
use of sterilized gloves, gowns, or draping (Gall et al.
1995; Heng et al. 2013; Verghese et al. 1998).
Two studies indicated decontamination of the skin
prior to tissue recovery. One study applied a 10 %
povidone iodine solution to the skin for 15 min while
the other simply indicated that the skin was ‘‘steril-
ized’’ for post-mortem tissue recoveries (Bettin et al.
1998; Gall et al. 1995). No other studies reported pre-




Following recovery, tissues were stored in a variety of
different solutions prior to processing. Recovered
cardiac tissues were immediately submerged in fluid
within sterile plastic bags in two studies (appendices F
and G) (Jashari et al. 2007; Verghese et al. 1998). Two
studies reported the use of saline, Ringer’s solution,
Eurocollins, UW, or tissue culture medium 199 with
HEPES buffer for storage (Goffin et al. 1996, 2000).
Jashari and associates utilized similar isotonic storage
solutions like saline, Ringer’s solution, tissue culture
medium 199, and Hank’s balanced salt solution, but
also indicated that solutions were constantly ‘‘main-
tained at 4 C’’ using ice.
Similar to cardiovascular tissue, tissue banks opted
to maintain the storage temperature of skin at 4 C,
when reported (Bravo et al. 2000; Castagnoli et al.
2003; Gaucher et al. 2012; Wester et al. 1998). The
recovered skin was submerged in Eagle’s minimum
essential medium (MEM) with Earle’s balanced salt
solution (BSS) without antibiotics at 4 C following
recovery in only one study (Wester et al. 1998). In the
remainder of the studies evaluating skin samples,
recovered tissue was submerged in solutions contain-
ing antibiotics. Rinsing of tissue (with saline)
566 Cell Tissue Bank (2016) 17:561–571
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following recovery was only reported by one study.
The rinsed samples were then submerged in X-Vivo
tissue culture mediumwith gentamicin (80 lg/ml) and
vancomycin (500 lg/ml) (Bravo et al. 2000). In the
remainder of studies, recovered skin was placed into
RPM1640 medium with 1 % serum albumin (supple-
mented with 100 lg/ml vancomycin, 50 lg/ml
trimethoprim-sulfametoxazole, 50 lg/ml fluconazole)
or Ringer’s lactate solution or RPMI 1640 medium
supplemented with gentamicin (320 mg/l), van-
comycin (500 mg/l) and lincomycin (600 mg/l)
(Castagnoli et al. 2003; Gaucher et al. 2012).
The transport and storage parameters of recovered
bone tissue were only reported in one study.
Recovered bone tissue was triple-wrapped in plastic
bags, containers, or both and stored at-70 (Campbell
and Oakeshott 1995).
Quality of clinical studies
Of the 12 clinical reports, one performed a prospective
cohort analysis (level II evidence) while the remaining
studies were retrospective analyses (level III evi-
dence). Using the GRADE assessment, the quality of
clinical studies according to the objectives was found
to range from very low to moderate (Table 2). The
clinical studies that addressed the time period between
asystole to skin preparation for tissue recovery were of







Donor Recovery site(s) Tissue(s) recovered
Chapman and
Villar (1992)
England 1 Cohort II Cadaveric
living











Belgium 1 Retrospective III Multi-organ OR or tissue
recovery room
Bone and tendon (following
organs)










Australia 1 Retrospective III Living OR Bone
Journeaux et al.
(1999)











Germany 1 Retrospective III Multi-organ
cadaveric
























Heart (prior to postmortem
evaluation)
Quality of evidence, Level I evidence: high, Level II evidence: moderate, Level III evidence: low, Level IV evidence: very low
OR operating room, NR not reported
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very low, to low quality. Additionally, clinical studies
that investigated the effect of body cooling or warm
ischemic times were of low quality. Clinical studies
that addressed skin preparation parameters, or that
included use of barriers to reduce contamination,
provided very low to moderate quality evidence. The
clinical studies that addressed excision techniques,
and post recovery storage conditions were of low
quality.
Confounding effects
Within an individual study many procedures are
standardized, but bioburden is rarely evaluated prior
to, and immediately following each recovery and
processing step. This makes it difficult to determine
their impact on bioburden. Of the 19 studies in this
review, bioburden following recovery or following
any bioburden reduction process was not reported.
Often, only the contamination rate was reported,
which provides insight into the number of samples
that are contaminated, but does not address the
efficacy of any methods to reduce the proportion of
contaminants, such as pre-recovery skin preparation,
or even warm ischemic time. Therefore, the efficiency
of decontamination efforts within the study cannot be
determined.
Similarly, the inclusion of multiple methods related
to one outcome also makes it difficult to assess the
efficacy of each method used to reduce bioburden.
Warm ischemic time, contamination barriers, skin
decontamination methods, skin recovery personnel
precautions, and recovery methods were all assessed
for their contribution towards the bioburden following
recovery. In each study, a standard protocol was
chosen for each of these parameters. The lack of a
reference or control method greatly inhibits the
confidence with which a process can be recommended.
Among different studies, the lack of consistency in
recovery protocols makes it difficult to determine the
most important variable(s) during the tissue recovery
process.
Additionally, the type of tissue recovered, as well as
the environment that the tissues were recovered in,
could affect bioburden outcome. Although most
studies reported isolation of tissues using aseptic
techniques, isolation of different tissues require
different protocols, and include different potential
sources of contamination.
Finally, variables such as donor skin condition
(abrasions, lacerations), presence of medical interven-
tions, cleanliness of skin, trauma, compound fractures,
and how they might correlate to bioburden load were
not reported.
Discussion
In this review, methods to reduce bioburden and the
contamination rate prior to, during, and following
tissue recovery were reviewed. The lowest rate of
contamination was found when warm ischemic time
was maintained below 24 h, and a team of two to six
surgeons performed the recovery of the bone tissue. In
one case report, the contamination rate was lowest
when five recovery personnel were involved in the
recovery process. Additional precautions, such as
maintaining warm ischemic times below 15 h, the use
of operating rooms as recovery sites, taking extra care
to not enter the abdominal cavity of the donor during
recovery of heart valves, or the use of sterile draping
during recovery, also demonstrated a lower contam-
ination rate (13.9 %). Interestingly, one of the highest
rates of contamination (average 46.7 %) was observed
when recovery precautions included the use of two
sets of instruments for recovery, double gloves, sterile
draping, shaving and scrubbing procedures, and the
use of 10 % povidone iodine for 15 min to decontam-
inate the skin, despite maintaining a recovery time less
than 24 h post asystole, and a maximum warm
ischemic time of 12 h.
Contamination rates may be correlated with the site
of tissue recovery. One of the studies observed lower
contamination rates in heart valves recovered from
multi-organ donors in operating rooms (12 %) com-
pared to valves recovered from cadavers in an open
mortuary (54 %) (Gall et al. 1995). Reduced contam-
ination during recovery in operating rooms was also
observed in three other studies (Gocke 2005; Jashari
et al. 2007; Schubert et al. 2012). Some studies
attribute this difference not to the room itself, but
instead to the classification of the donor (i.e., tissue
recovery from a multi-organ donor or living donor
occurs in an operating room, whereas a deceased
donor of tissues may be located in a morgue when
recovery takes place) (Journeaux et al. 1999; Schubert
et al. 2012). In contrast, Gall et al. (1995) attributes the
increased contamination in the morgue to the
568 Cell Tissue Bank (2016) 17:561–571
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atmosphere of the room, given that the most common
species identified were skin and respiratory flora (Gall
et al. 1995). One study reported the opposite trend of
higher contamination in the operating room compared
to the morgue (51 % and 40 %, respectively) (Bettin
et al. 1998). However, the study also showed that
microorganisms contaminating allografts from the
morgue were more likely to be pathogenic (e.g. S.
aureus, E. coli, Candida) compared to the operating
room (Bettin et al. 1998). Within North America, the
American Academy of Orthopaedic Surgeons states
that tissue should be recovered aseptically in an
operating room and not the morgue, and within 24 h of
the donor’s death (Gitelis and Wilkins 2011). The
reports in this review support these standardized
practices, despite potentially higher contamination
rates with non-pathogenic microorganisms.
One variable of tissue recovery that may impact
contamination is time from asystole to time of tissue
recovery and whether body cooling occurred. Cur-
rently, the literature is not sufficient to determine
whether the time interval from asystole to tissue
recovery or warm ischemic time is a better predictor of
contamination; however, studies have indicated that in
general, a reduction in the time period between
asystole to tissue recovery is an important contributor
to contamination. For example, heart valves recovered
from non-heart beating donors (\6 h warm ischemic
time, or\36 h recovery time) had a significantly
lower contamination rate compared to valves from
beating-heart donors (i.e. the interval from asystole to
tissue recovery is considered to be near to 0 h) (Goffin
et al. 2000). Another study recommended bone
recovery within 24 h of asystole to reduce the
overgrowth of skin microorganisms (Journeaux et al.
1999). Vehmeyer et al. (2002) have demonstrated that
the risk of blood contamination increased each hour
following asystole (cessation of heart beating), sug-
gesting post-mortem time to recovery should be kept
to a minimum (Vehmeyer et al. 2002). Similarly, the
warm ischemic time has been kept to a minimum in all
studies, when reported, as some studies have shown
that cooling the body may reduce the bioburden. At
lower temperatures, the growth rate of many bacteria
is diminished (Ratkowsky et al. 1983, 1982).
Other pre-recovery variables did not appear to be
correlated with a decrease in contamination rates. For
example, the use of skin decontamination steps or
physical barriers did not appear to decrease
contamination rates. Higher rates of contamination
were reported when skin decontamination was per-
formed (average contamination rate of 52.5 %) com-
pared to other studies where a method to
decontaminate skin was not reported (average con-
tamination rate of 19.9 %).
Different tissues may experience different rates of
contamination. The average contamination rates of
cardiac tissues are slightly greater than bone (approx-
imately 28 vs. 23 %), but this may be attributed to a
more intensive culture protocol (Sommerville et al.
2000). The highest rates of bone contamination
occurred in allografts that were recovered after the
removal of organs (Bettin et al. 1998). Contrarily,
Segur et al. (1998) observed that the initial removal of
other organs did not impact bone contamination,
suggesting other factors may be important for con-
tamination during recovery.
Limitations
In this systematic review, the most effective methods
of tissue recovery to minimize contamination are
addressed. Overall, the quality of included studies
ranged from low to moderate. No data regarding tissue
recovery order, donor skin condition, presence of
trauma or compound fractures, or the hygiene, pres-
ence of an acute illness, or open lesions in tissue
recovery personnel were reported.
The contamination rate outcome was utilized to
determine the most effective methods to reduce
contamination following recovery. There was a large
amount of heterogeneity in the culturing methods to
identify the presence of microorganisms. Some organ-
isms are extremely fastidious, and may only grow
within a narrow range of nutrient and environmental
conditions. Most studies used media types that are
proposed to be able to capture the majority of
organisms that may contaminate the tissues, but the
use of only one culture medium or incubation param-
eter could possibly exclude important pathogens that
would affect transplantation outcomes. The swab
culture method has been reported to have a low
recovery efficiency (9–10 %), suggesting that it is
unreliable for the detection of the majority of
microorganisms (Veen et al. 1994). Additionally,
some organisms are extremely fastidious, and may
only grow within a narrow range of nutrient and
environmental conditions, which can further reduce
Cell Tissue Bank (2016) 17:561–571 569
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detection. Sommerville et al. (2000) noted that the
development of deep infections in allograft recipients
were due to organisms that were not cultured, but were
still present on the allograft after decontamination.
A number of studies suggested that the time
between asystole and skin preparation could con-
tribute to allograft contamination. However, there
were insufficient data to determine whether warm
ischemic time or asystole to tissue recovery interval
was a better predictor of contamination. One study
examined the effects of variable warm ischemic times
and was able to determine a precise relationship with
cell viability, but the bioburden was not addressed
(Niwaya et al. 1995).
Finally, all of the studies did not address the
bioburden reduction capabilities of the tissue recovery
methods used. As opposed to the contamination rate,
the reduction in bioburden value can quantitatively
show the effectiveness of decontamination methods,
and allows for further optimization.
Conclusions
Understanding the factors that may promote or inhibit
microorganism contamination of allografts during
tissue recovery can decrease the number of discarded
tissues and/or processed allografts, and could improve
the safety of allograft transplantation by minimizing
the potential for infection or other complications post
surgery. The results of this review suggest that
minimizing recovery times (\24 h) and the number
of personnel performing tissue recovery are the
greatest factors affecting the rate of tissue contamina-
tion at or following recovery. Reduction of the
contamination rate is also associated with reduced
recovery time (i.e., warm ischemic times\6 h), and
the use of exclusive recovery sites such as an operating
room also result in a marked decrease in the contam-
ination rate. The experience of the recovery team, as
well as the number of recovery personnel may also
affect the level of contamination observed. The use of
povidone iodine to decontaminate skin, multiple sets
of sterile instruments, and double gloving do not
appear to result in a great reduction of the contami-
nation rate. Due to the lack of information, it cannot be
concluded if the use of barriers and/or hygienic
precautions taken by personnel to reduce transmission
of contaminants have an effect on the contamination
rate or bioburden following tissue recovery. Con-
trolled studies in this area are lacking and should be
pursued by tissue banking professionals so methods
employed to reduce or control bioburden are sup-
ported by evidence-based data.
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